Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kamada Ltd. (KMDA : NSDQ)

• Company Description    Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. Number of Employees: 462

• Price / Volume Information    Yesterday's Closing Price: $7.77 Daily Weekly Monthly 20 Day Moving Average: 79,541 shares Shares Outstanding: 57.51 (millions) Market Capitalization: $446.81 (millions) Beta: 0.89 52 Week High: $9.35 52 Week Low: $6.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.01% -11.08% 12 Week 9.44% 6.77% Year To Date 10.06% -2.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HOLTZMAN ST. SCIENCE PARK - REHOVOT,L3 7670402 ISR ph: 972-8940-6472 fax: 972-8940-6473 ir@kamada.com http://www.kamada.com

• General Corporate Information    Officers Amir London - Chief Executive Officer Lilach Asher-Topilsky - Chair of the Board of Directors Eran Nir - Chief Operating Officer Chaime Orlev - Chief Financial Officer Uri Botzer - Director Peer Information Kamada Ltd. (CORR.) Kamada Ltd. (RSPI) Kamada Ltd. (CGXP) Kamada Ltd. (BGEN) Kamada Ltd. (GTBP) Kamada Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M6240T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 57.51 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $446.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 1.64% Current Fiscal Quarter EPS Consensus Estimate: $0.12 Indicated Annual Dividend: $0.13 Current Fiscal Year EPS Consensus Estimate: $0.48 Payout Ratio: 0.49 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.43 Estmated Long-Term EPS Growth Rate: 25.00% Last Dividend Paid: 08/27/2026 - $0.13 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: 16.30 Trailing 12 Months: 20.45 PEG Ratio: 0.65 Price Ratios Price/Book: 1.66 Price/Cash Flow: 12.72 Price / Sales: 2.33 EPS Growth vs. Year Ago Period: 23.08% vs. Previous Quarter: 128.57% Sales Growth vs. Year Ago Period: 22.72% vs. Previous Quarter: 21.40% ROE 09/30/26 - - 06/30/26 - 8.37 03/31/26 - 7.73 ROA 09/30/26 - - 06/30/26 - 5.85 03/31/26 - 5.41 Current Ratio 09/30/26 - - 06/30/26 - 4.06 03/31/26 - 3.33 Quick Ratio 09/30/26 - - 06/30/26 - 2.29 03/31/26 - 1.90 Operating Margin 09/30/26 - - 06/30/26 - 11.60 03/31/26 - 11.21 Net Margin 09/30/26 - - 06/30/26 - 11.60 03/31/26 - 11.21 Pre-Tax Margin 09/30/26 - - 06/30/26 - 13.91 03/31/26 - 12.24 Book Value 09/30/26 - - 06/30/26 - 4.69 03/31/26 - 4.51 Inventory Turnover 09/30/26 - - 06/30/26 - 1.33 03/31/26 - 1.27 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©